[Treatment of patients with recurrent superficialbladder cancer with lyophilized Moureau-Rio de Janeiro BCG strain.Brazillian National Cancer Institute experience]
Links [Treatment of patients with recurrent superficial bladder cancer with lyophilized Moureau-Rio de Janeiro BCG strain. Brazillian National Cancer Institute experience] [Article in French] Quirino R, Ornellas AA, Wisnescky AProg Urol. 2005 Sep;15(4):667-73. Links [Treatment of patients with recurrent superficial bladder cancer with lyophilized Moureau-Rio de Janeiro BCG strain. Brazillian National Cancer Institute experience] [Article in French] Quirino R, Ornellas AA, Wisnescky A. Departement d'Urologie, Institut National du Cancer, Rio de Janeiro, Bresil. PURPOSE: We present our experience with lyophilized Moureau-Rio de Janeiro BCG strain for treatment of patients with recurrent superficial bladder cancer. PATIENTS AND METHODS: From October 1986 to January 2001, 114 patients were treated by transurethral resection followed by intravesical instillation of BCG at our institution. Follow-up ranged from 10 to 144 months (mean 50.16 months). The treatment included 6 inductions and 10 maintenance cycles of BCG instillations. The patients received an initial dose with 40 mg and subsequent doses with 80 mg of lyophilized Moureau-Rio de Janeiro BCG strain. Chi-square and Mantel-Haenszel test, with 95% significance, were used to evaluate possible associations among variables. The Kaplan-Meyer method was used to evaluate the disease-free survival rates while log-rank test was used to compare curves among the groups. RESULTS: Overall recurrence and progression rates after treatment were 45.6% and 13%, respectively. Four patients (3.5%) had complications following BCG instillations. Three of them had to be treated with antituberculous therapy. These patients presented pulmonary disease, granulomatous prostatitis and epididymo-orchitis respectively. CONCLUSIONS: Moureau-Rio de Janeiro BCG strain was overall well tolerated in intravesical instillations, similar to other strains used in literature. Recurrence rates were decreased with adjuvant BCG therapy. Tumor size, grade and presence of associated carcinoma in situ provided predictive information regarding the behavior of recurrent superficial tumors. The WHO/ISUP classification when compared with tumor grade was superior in selecting patients with high risk of progression. PMID: 16459683 [PubMed - indexed for MEDLINE] Related Links Treatment of patients with superficial bladder cancer stratified by risk groups treated with lyophilized Moreau-Rio de Janeiro BCG strain. [Int Braz J Urol. 2002] PMID: 15748368 Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guerin: 18-year experience. [Urology. 2002] PMID: 11834391 Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer. [Int J Urol. 2005] PMID: 15948743 Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. [J Urol. 2000] PMID: 10737480 Recurrence, progression and success in stage Ta grade 3 bladder tumors treated with low dose bacillus Calmette-Guerin instillations. [J Urol. 2000] PMID: 10604315 See all Related Articles... Display Summary Brief Abstract AbstractPlus Citation MEDLINE XML UI List LinkOut ASN.1 Related Articles Cited Articles Cited in Books CancerChrom Links Domain Links 3D Domain Links GEO DataSet Links Gene Links Gene (GeneRIF) Links Genome Links Project Links GENSAT Links GEO Profile Links HomoloGene Links Nucleotide Links Nucleotide (RefSeq) Links OMIA Links OMIM (calculated) Links OMIM (cited) Links BioAssay Links Compound Links Compound via MeSH Substance Links Substance via MeSH PMC Links Cited in PMC PopSet Links Probe Links Protein Links Protein (RefSeq) Links SNP Links Structure Links Taxonomy via GenBank UniGene Links UniSTS Links Show 5 10 20 50 100 200 500 Sort by Pub Date First Author Last Author Journal Send to Text File Printer Clipboard E-mail Order .
Departement d'Urologie, Institut National du Cancer, Rio de Janeiro, Bresil.
PURPOSE: We present our experience with lyophilized Moureau-Rio de Janeiro BCG strain for treatment of patients with recurrent superficial bladder cancer. PATIENTS AND METHODS: From October 1986 to January 2001, 114 patients were treated by transurethral resection followed by intravesical instillation of BCG at our institution. Follow-up ranged from 10 to 144 months (mean 50.16 months). The treatment included 6 inductions and 10 maintenance cycles of BCG instillations. The patients received an initial dose with 40 mg and subsequent doses with 80 mg of lyophilized Moureau-Rio de Janeiro BCG strain. Chi-square and Mantel-Haenszel test, with 95% significance, were used to evaluate possible associations among variables. The Kaplan-Meyer method was used to evaluate the disease-free survival rates while log-rank test was used to compare curves among the groups. RESULTS: Overall recurrence and progression rates after treatment were 45.6% and 13%, respectively. Four patients (3.5%) had complications following BCG instillations. Three of them had to be treated with antituberculous therapy. These patients presented pulmonary disease, granulomatous prostatitis and epididymo-orchitis respectively. CONCLUSIONS: Moureau-Rio de Janeiro BCG strain was overall well tolerated in intravesical instillations, similar to other strains used in literature. Recurrence rates were decreased with adjuvant BCG therapy. Tumor size, grade and presence of associated carcinoma in situ provided predictive information regarding the behavior of recurrent superficial tumors. The WHO/ISUP classification when compared with tumor grade was superior in selecting patients with high risk of progression.
This abstract is being posted for educational purposes, as well as for comment and criticism, by the visitors to the Epididymitis Foundation website (www.EpididymitisFoundation.org). This abstract is representative of a larger article that is indexed on Medline.
Men's Health Web Ring
SurvivingProstateCancerWithoutSurgery.org
VasectomyFoundation.org
Prostatitis Foundation
( Prostatitis.org)
Disclaimer: Information provided on this web site is for educatonal purposes only. It is not a substitute for, nor can it replace advice from your own physician. The information on this site is not to be used for diagnosing or treating any health concerns that you may have. Testicular torsion, which is a medical emergency can be confused with epididymitis. You must see your own physician for diagnosis and treatment. Furthermore, the information on this site is never guaranteed to be 100% accurate or 100% up to date. All the side effects of mentioned treatments, drugs, surgeries, or therapies cannot always be listed or be known. Errors and omissions may occur in any essay. See a competent physician for your health care needs.
EpididymitisFoundation.org™ Established December 11, 2002
